Can An Artificial Heart Replace Transplants? with Patrick Schnegelsberg, CEO at SynCardia

In this Crux of Medtech crossover with the new Crux of Cardio series, Jordan and Henry sit down with Jack, his wife and caregiver Rocky, and SynCardia CEO Patrick Schnegelsberg to explore what a total artificial heart really means at the bedside and in the boardroom.Key Topics- Jack’s journey from misdiagnosis to ejection fraction of five to ten percent- ICU course, ECMO, cardiac arrest and the decision point for total artificial heart- Rocky’s lived reality as caregiver through transplant listing and repeated setbacks- How SynCardia’s pneumatic total artificial heart works as a bridge to transplant- Patient selection trade-offs between LVADs, ECMO, bivads and total artificial heart- Why SynCardia is now pursuing a fully implantable “Emperor” artificial heart platformRelated Insights- Emotional and cognitive load when a clinician becomes a critical care patient- The impact of early education and MCS teams on acceptance of advanced devices- How device simplicity and Frank–Starling physiology shape SynCardia’s design choices- Awareness gaps among cardiology and surgical teams around total artificial heart options- The role of transplant center experience and volume in total artificial heart outcomes- Long-term vision for artificial hearts as a true alternative to donor transplantation.Core Challenges- Recognising when a patient has moved beyond LVAD and inotrope support- Balancing end-organ failure risk against surgical risk and infection concerns- Managing caregiver stress during long ICU stays and on–off transplant listing- Overcoming historical perceptions and “old tech” stigma around artificial hearts- Funding and scaling class III cardiovascular hardware in a niche but severe populationTune in now to hear how total artificial hearts are reshaping advanced heart failure care, from one family’s story at the bedside to SynCardia’s plans for fully implantable devices.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠